PVD, Retinal Breaks, and Lattice Degeneration PPP
Background:
Posterior vitreous detachment (PVD) is a separation of the posterior vitreous cortex from the internal limiting membrane of the retina. Retinal breaks are defined as full-thickness defects in the retina. Lattice degeneration is a peripheral vitreoretinal condition characterized by retinal thinning, overlying vitreous liquefaction, and firm vitreoretinal adhesions at the margins of thinning.
A PVD typically occurs between the ages of 45 and 65 in the general population with earlier onset in men; however, the posterior vitreous may detach earlier in trauma and myopia. PVD may lead to vitreomacular traction (VMT), potentially leading to mechanical distortion of the macula or to retinal tears and potentially retinal detachment. The recommendations of this Preferred Practice Pattern (PPP) are based on Cochrane-identified reliable systematic reviews.
Rationale for treatment:
The patient outcome criteria and rational for treatment for PVD and RRD include the prevention of visual loss and functional impairment and maintenance of quality of life. If patients are familiar with the symptoms of retinal tears or detachment, they are recommended to report promptly, thus improving the opportunity for successful treatment.
Care Process: The care process for a patient starts with all the elements of a comprehensive adult eye evaluation with attention to risk factors relevant for a PVD, retinal breaks, and lattice degeneration. Additionally, a PVD should be evaluated for vitreous pigmented cells and includes a thorough peripheral examination looking for retinal tears or holes.
Management recommendations are detailed in this PPP, which includes surgical management, complications of treatment and follow-up evaluation. At the time of this published PPP, there are no effective methods of preventing the factors that lead to PVD. All patients at increased risk of retinal detachment should be instructed to notify their ophthalmologist as soon as possible if they have a substantial change in symptoms (e.g., increased floaters, loss of visual field, or decrease in visual acuity). Patients who undergo refractive surgery to reduce myopia should be informed that they remain at risk of RRD despite reduction of their refractive error.
P228
P228 As a service to its members and the public, the American Academy of Ophthalmology has developed a series of Preferred Practice Pattern® guidelines that identify characteristics and components of quality eye care. Appendix 1 describes the core criteria of quality eye care.
The Preferred Practice Pattern® guidelines are based on the best available scientific data as interpreted by panels of knowledgeable health professionals. In some instances, such as when results of carefully conducted clinical trials are available, the data are particularly persuasive and provide clear guidance. In other instances, the panels have to rely on their collective judgment and evaluation of available evidence.
These documents provide guidance for the pattern of practice, not for the care of a particular individual. While they should generally meet the needs of most patients, they cannot possibly best meet the needs of all patients. Adherence to these PPPs will not ensure a successful outcome in every situation. These practice patterns should not be deemed inclusive of all proper methods of care or exclusive of other methods of care reasonably directed at obtaining the best results. It may be necessary to approach different patients' needs in different ways. The physician must make the ultimate judgment about the propriety of the care of a particular patient in light of all of the circumstances presented by that patient. The American Academy of Ophthalmology is available to assist members in resolving ethical dilemmas that arise in the course of ophthalmic practice.
Preferred Practice Pattern® guidelines are not medical standards to be adhered to in all individual situations. The Academy specifically disclaims any and all liability for injury or other damages of any kind, from negligence or otherwise, for any and all claims that may arise out of the use of any recommendations or other information contained herein.
References to certain drugs, instruments, and other products are made for illustrative purposes only and are not intended to constitute an endorsement of such. Such material may include information on applications that are not considered community standard, that reflect indications not included in approved U.S. Food and Drug Administration (FDA) labeling, or that are approved for use only in restricted research settings. The FDA has stated that it is the responsibility of the physician to determine the FDA status of each drug or device he or she wishes to use, and to use them with appropriate patient consent in compliance with applicable law.
Innovation in medicine is essential to ensure the future health of the American public, and the Academy encourages the development of new diagnostic and therapeutic methods that will improve eye care. It is essential to recognize that true medical excellence is achieved only when the patients' needs are the foremost consideration.
All Preferred Practice Pattern® guidelines are reviewed by their parent panel annually or earlier if developments warrant and updated accordingly. To ensure that all PPPs are current, each is valid for 5 years from the approved by date unless superseded by a revision. Preferred Practice Pattern guidelines are funded by the Academy without commercial support. Authors and reviewers of PPPs are volunteers and do not receive any financial compensation for their contributions to the documents. The PPPs are externally reviewed by experts and stakeholders, including consumer representatives, before publication. Preferred Practice Pattern® guidelines should be clinically relevant and specific enough to provide useful information to practitioners. Where evidence exists to support a recommendation for care, the recommendation should be given an explicit rating that shows the strength of evidence. To accomplish these aims, methods from the Scottish Intercollegiate Guideline Network 1 (SIGN) and the Grading of Recommendations Assessment, Development and Evaluation 2 (GRADE) group are used. GRADE is a systematic approach to grading the strength of the total body of evidence that is available to support recommendations on a specific clinical management issue. Organizations that have adopted GRADE include SIGN, the World Health Organization, the Agency for Healthcare Research and Policy, and the American College of Physicians. 3 ◆ All studies used to form a recommendation for care are graded for strength of evidence individually, and that grade is listed with the study citation.
◆ To rate individual studies, a scale based on SIGN 1 is used. The definitions and levels of evidence to rate individual studies are as follows:
I++
High-quality meta-analyses, systematic reviews of randomized controlled trials (RCTs), or RCTs with a very low risk of bias I+ Well-conducted meta-analyses, systematic reviews of RCTs, or RCTs with a low risk of bias I-Meta-analyses, systematic reviews of RCTs, or RCTs with a high risk of bias II++ High-quality systematic reviews of case-control or cohort studies High-quality case-control or cohort studies with a very low risk of confounding or bias and a high probability that the relationship is causal II+ Well-conducted case-control or cohort studies with a low risk of confounding or bias and a moderate probability that the relationship is causal II-Case-control or cohort studies with a high risk of confounding or bias and a significant risk that the relationship is not causal III Nonanalytic studies (e.g., case reports, case series) ◆ Recommendations for care are formed based on the body of the evidence. The body of evidence quality ratings are defined by GRADE 2 as follows: Used when the trade-offs are less certain-either because of low-quality evidence or because evidence suggests that desirable and undesirable effects are closely balanced ◆ The Highlighted Findings and Recommendations for Care section lists points determined by the PPP Panel to be of particular importance to vision and quality of life outcomes. ◆ All recommendations for care in this PPP were rated using the system described above. Ratings are embedded throughout the PPP main text in italics. Population-based studies that evaluate incidence and prevalence of PVD are difficult to conduct owing to the lack of definite clinical signs and unreliable clinical tests. A PVD typically occurs between the ages of 45 and 65 in the general population with earlier onset in men than women;
however, the posterior vitreous may detach earlier in trauma and myopia, or be precipitated by ophthalmic surgical procedures. 5, [7] [8] [9] Posterior vitreous detachment leads to vitreous traction at the vitreous base and in areas of lattice degeneration, and thereby, secondarily, is thought to cause most symptomatic retinal breaks that may lead to an RRD. The symptoms of a PVD include light flashes (photopsias) and floaters (myodesopias), and patients with such symptoms are at a higher risk for retinal detachment. [10] [11] [12] [13] [14] The stages of a PVD are described in Table 1 . 4 Patients typically report the light flashes characteristic of a PVD as being most noticeable in the dark. Such photopsias are likely the result of vitreous traction on the retina as the vitreous separates from the posterior retina toward the vitreous base. The floaters may be due to blood from a torn or avulsed retinal vessel, condensations of vitreous collagen, or the epipapillary glial tissue (Weiss ring) that is torn from the optic nerve head and area adjacent to the optic nerve head. Between 8% and 22% of patients with acute PVD symptoms have a retinal tear at the time of the initial examination. [15] [16] [17] [18] There is a direct correlation between the amount of vitreous hemorrhage and the likelihood of a retinal tear. 19 Patients with an acute PVD who have no reported retinal breaks on presentation have a 2% to 5% chance of experiencing a detected (missed or new) break in the weeks that follow. 13, 16, 20 Approximately 80% of patients who presented without detected breaks, and then had breaks occur subsequently, had either pigmented cells or hemorrhage in the vitreous or retina at the initial evaluation, or new symptoms that prompted a return visit to the ophthalmologist. 16 A spontaneous vitreous hemorrhage can be the presenting sign of PVD or may occur during the evolution of the PVD. Two-thirds of patients who present with associated vitreous hemorrhage were found to have at least one break. In this subgroup, one-third had more than one break and approximately 88% of the breaks occurred in the superior quadrants. 22 Precursors to RRDs are PVD, asymptomatic retinal breaks, symptomatic retinal breaks, lattice degeneration, and cystic and zonular traction retinal tufts. (See Glossary.) Because spontaneous retinal reattachment is rare, nearly all patients with a symptomatic clinical RRD will progressively lose vision unless the detachment is repaired. Currently, more than 95% of uncomplicated RRDs can be successfully repaired, although more than one procedure may be required. 23 The prophylactic treatment of high-risk breaks usually prevents RRD. An early diagnosis of an RRD is also important because the rate of successful reattachment is higher and the visual results are better when repaired early and especially before the RRD involves the macula. 15, 17 The goal of RRD treatment is to allow patients to maintain their abilities to read, work, drive, care for themselves, and maintain their quality of life. 18 Asymptomatic operculated holes and atrophic round holes rarely lead to retinal detachment.
Byer followed 46 asymptomatic eyes with operculated retinal breaks over an average of 11 years. 24 Davis followed 28 eyes for up to 5 years in subjects where 80% of the fellow eyes had a retinal detachment. 25, 26 All combined, none of the 74 eyes from these studies progressed to retinal detachment during the follow-up period.
Eyes with signs and symptoms of acute PVD may have atrophic retinal breaks with clinical features, suggesting that they are unrelated to the acute vitreoretinal traction from the PVD.
Such breaks are considered to be pre-existing rather than symptomatic. Treatment may be considered for these breaks in certain situations, although the literature provides little guidance. 26 Randomized clinical trials are not available; therefore, there is limited evidence to support prophylactic therapy. 26 Approximately 5% of eyes with asymptomatic horseshoe tears progress to retinal detachment. 24, 27, 28 Horseshoe tears discovered in asymptomatic fellow eyes are less likely than Glossary) . 35, 36 Although these can enlarge and progress to clinical retinal detachments, they have been shown by observation alone to have a low likelihood of progression in most patients. 35 Prophylactic or interventional treatment should be considered when the detachments are documented to become symptomatic, increase in size, or show other signs of progression. 27, 37 One analysis studied 423 eyes with lattice degeneration in 276 patients over a period averaging nearly 11 years. 37 Of these, 150 eyes (35%) had atrophic holes in lattice, and 10 of these 150 More commonly, RRD occurs in eyes with lattice degeneration when a PVD induces a horseshoe tear. Such tears should be treated using either laser demarcation or cryotherapy. 27, 37 The annual incidence of RRD is approximately 10 to 18 per 100,000 persons. [38] [39] [40] Of these, 20% to 40% have had cataract surgery and 10% have had ocular trauma. 23, 41, 42 In a recent study from the Netherlands, the annual RRD incidence was 18 per 100,000 people (95% CI, 11-19), with a peak incidence of 53 per 100,000 people (95% CI, 29-57) between 55 and 59 years of age. The rate of bilateral RRD was 1.7%. Prior cataract surgery was reported in 34% of RRD eyes. 40 Aside from retinal breaks, risk factors for RRD include myopia, lattice degeneration, cataract or other intraocular surgery, neodymium yttrium-aluminum-garnet (Nd:YAG) laser surgery, trauma, a history of RRD in the other eye, certain genetic disorders such as Stickler syndrome, or family history of retinal detachments in a first-degree relative. Combinations of these factors may increase the risk.
More than half of nontraumatic RRD occurs in myopic eyes. 43 As axial length increases, the risk of RRD increases proportionately. One study found that individuals with low myopia (1-3 diopters) have a fourfold risk of RRD, 43 and higher levels of myopia have higher risks compared with nonmyopic individuals. 43, 44 Lattice degeneration is present in 6% to 8% of the population and increases the risk of retinal detachment. 37, 45 Approximately 20% to 30% of patients with RRD have lattice degeneration. 37 Perivascular or radial lattice is associated with a higher risk of retinal tear or detachment formation. 37 Perivascular lattice it is also frequently seen in Stickler syndrome. 46 The overall risk of RRD after cataract surgery is approximately 1%. [47] [48] [49] [50] The following conditions have been reported to increase the risk of RRD after cataract surgery: axial myopia, pre-existing vitreoretinal disease, male gender, younger age, vitreous prolapse into the anterior chamber, vitreous loss (ruptured posterior capsule/zonules), and spontaneous extension of the capsulotomy at the time of surgery. 51, 52 One study suggests that in the absence of a posterior capsular tear at the time of cataract surgery, subsequent Nd:YAG laser capsulotomy may not increase the risk of retinal detachment. 53 Other studies suggest that Nd:YAG laser capsulotomy is associated with a fourfold increase in the risk of RRD, especially in myopic patients. 41, 42, [54] [55] [56] [57] [58] [59] [60] [61] Outside of complications at the time of surgery, risk of RRD after cataract surgery usually occurs 1 to 2 years later. A 5-year study using B-scan ultrasonography reported that it was the postoperative onset of a PVD that was the major risk factor for RRD (not the presence or absence of lattice) after cataract surgery and that the majority of eyes after cataract surgery that did not have a pre-existing PVD developed one at a median of 7 months after surgery.
Consequently, one can extrapolate that it is the absence of a PVD (in higher risk eyes such as those with myopia and lattice) at the time of cataract surgery that is the major risk of RRD later. 60 Patients with blunt or penetrating ocular injuries that have altered the structure of the vitreous or retina are at increased risk of RRD. 62 Vitreoretinal interface changes caused by trauma may be detected at the time of injury or even many years later.
Patients with a history of nontraumatic detachment in one eye have a 10% increased risk of developing RRD in the fellow eye, since pathologic vitreoretinal changes are frequently bilateral. 27, 39, [63] [64] [65] The fellow eye in a patient with pseudophakic retinal detachment is also at higher risk of developing a retinal detachment, whether the fellow eye is phakic or pseudophakic. Phakic fellow eyes in patients with pseudophakic retinal detachment have a 7% risk of RRD, suggesting that the risk of developing RRD should not be attributed to cataract surgery alone. 66 Other risk factors that have been reported include prior retinopathy of prematurity 67 and Stickler syndrome. 68, 69 There are case reports of retinal detachment in patients who have had keratorefractive surgery;
however, large studies have not shown an increased risk in patients when compared with eyes of a similar refractive error. 70, 71 It remains possible that the risk of vitreoretinal pathology is different among particular keratorefractive techniques. 9 Retinal detachment following refractive lens exchange in patients with high myopia showed a cumulative increase from 2% to 8% over a 7-year incidence. 72 Phakic intraocular lenses have not been associated with increased risk of retinal detachment compared with other intraocular interventions in highly myopic patients. 71, 73, 74 For management and treatment for PVD and RRD, the following outcomes are important: A patient history should include the following elements: ◆ Careful examination of the peripheral fundus using scleral depression 82 (see Table 3 )
There are no symptoms that can reliably distinguish between a PVD with or without an associated retinal break; therefore, a peripheral retinal examination is required. 82 The preferred method of evaluating patients for peripheral vitreoretinal pathology is to use an indirect ophthalmoscope combined with scleral depression. 83 Many patients with retinal tears have blood and pigmented cells in the anterior vitreous. In fully dilated eyes, slit-lamp biomicroscopy with a mirrored contact lens or a condensing lens is an alternative method in fully dilated eyes instead of a scleral depressed indirect examination of the peripheral retina.
Optical coherence tomography may be helpful to evaluate and stage the PVD. 4 found that there is also no strong evidence in the literature to support or refute the use of 360degree laser intervention in the fellow eyes of patients with a unilateral giant retinal tear. 93 Pharmacotherapy for the management of VMT has been developed. In a placebo-controlled trial of microplasmin (a precursor of ocriplasmin) to induce a PVD, intravitreal injection of 125 micrograms of microplasmin led to a moderate increase in the likelihood of induction and progression of PVD (10% vs. 31%). 84 Please refer to the Idiopathic ERM and VMT PPP for a detailed discussion. 6 The analysis showed that ocriplasmin was better than sham or placebo for inducing PVD, although adverse events were more common in the treated group. In addition, 20% still needed pars plana vitrectomy within 6 months. 94 Pneumatic vitreolysis is also used to induce a PVD. In a meta-analysis, pneumatic vitreolysis approached similar release rates of pars plana vitrectomy and was more effective than ocriplasmin by day 28. 95 Complications of this procedure are typically related to PVD formation and include retinal tear, retinal detachment, epiretinal membrane, and lamellar or macular hole formation. 94, 95 It is essential that clinical personnel be familiar with the symptoms of PVD and retinal detachment and that they recognize the need for urgent ophthalmologic evaluation of symptomatic patients. 14 vitrectomy is an option if symptomatic floaters are still bothersome after several months. In fact, it has been documented using contrast sensitivity function, that patients with a PVD have a significant reduction in contrast sensitivity function. 97 Laser treatments and pharmacotherapies have been proposed to decrease these symptoms; however, such therapies currently lack sufficient evidence to support their use. 98 Pars plana vitrectomy has been used for removal of floaters, and improvement in contrast sensitivity function has been documented. 99 In a recent review of series that compared pars plana vitrectomy and Nd:YAG laser for floaters, 100 pars plana vitrectomy showed evidence of greater patient satisfaction compared with only moderate resolution of symptoms following the Nd:YAG laser procedure. Another study found YAG vitreolysis to yield greater improvement in symptoms than sham laser. 101 The goal of treatment for retinal breaks is to create a firm chorioretinal adhesion in the attached retina immediately adjacent to and surrounding the retinal tear using cryotherapy or laser photocoagulation surgery to halt the progression of subretinal fluid from detaching the neurosensory retina.
Treatment of peripheral horseshoe tears should be extended to the ora serrata if the tear cannot be surrounded using laser or cryotherapy. 31, 102, 103 The most common cause of failure in treating horseshoe tears is failure to adequately treat the tear, particularly at the anterior border.
Continued vitreous traction may extend the tear beyond the treated area and allow fluid to dissect through the subretinal space to cause a clinical retinal detachment. 31, 102, 103 Treatment of dialyses must extend over the entire length of the dialysis, reaching the ora serrata beyond each horn or end of the dialysis.
Sufficient evidence exists to warrant treating acute, symptomatic horseshoe tears. 25 There is insufficient evidence for management of other vitreoretinal abnormalities. A Cochrane systematic review found that in making the decision to treat other vitreoretinal abnormalities, including lattice degeneration and asymptomatic retinal breaks, that the risks that treatment would be unnecessary, ineffective, or harmful must be weighed against the possible benefit of reducing the rate of subsequent retinal detachment. 26 (I+, Good quality, Strong recommendation) Table 2 summarizes recommendations for management. A Cochrane systematic review in 2014 shows that no randomized controlled clinical trials have been performed to support treatment of asymptomatic retinal breaks of lattice degeneration. 26 There is no level 1 evidence to support the use of prophylactic laser to areas of lattice degeneration prior to anterior segment surgery. 63, 65 A primary limitation of prophylactic therapy is that causative breaks leading to retinal detachment often occur during a PVD in areas that appear normal prior to the PVD. 65 The surgeon should inform the patient of the risks, benefits, and alternatives to surgery. 104, 105 The treating surgeon is responsible for formulating a postoperative care plan and should inform the patient of these arrangements. 104, 105 Retinal detachments may occur in spite of appropriate therapy. Traction is an important component and may pull the tear from the treated area, especially when there are larger breaks or bridging retinal blood vessels. The laser-or cryotherapy-induced treatment adhesion (chorioretinal scar) may not be firm or complete for up to 1 month following treatment. 31, 33, 102 Furthermore, 10% to 16% of patients will develop additional breaks during long-term followup. 33, 106, 107 Pseudophakic patients are more likely to require retreatment or to develop new breaks. 33 Proliferation of the epiretinal membrane (ERM), or macular pucker, has been occasionally observed following treatment for a retinal break; however, a direct cause and effect relationship of treatment of a retinal break to ERM remains unclear, since an ERM may also occur spontaneously following the PVD. (See Glossary.) In one long-term follow-up study, the percentage of eyes that developed macular pucker after treatment of retinal breaks was no greater than the percentage of eyes observed to have macular pucker before treatment. 31 Therefore, the method of creating a chorioretinal adhesion may be unrelated to the incidence of postoperative macular pucker. 108 The guidelines in Table 3 detachments. Treatment should be considered if the detachments progress in size. 27, 37 Patients presenting with an acute PVD and no retinal breaks have a small chance (approximately 2%) of developing retinal breaks in the weeks that follow. 13 Thus, selected patients, particularly those with any degree of vitreous pigment, vitreous or retinal hemorrhage, or visible vitreoretinal traction, should be asked to return for a second examination within 6
weeks following the onset of symptoms. 13, 107 A patient history should identify changes in the following:
◆ Visual symptoms [10] [11] [12] [13] [14] 81 ◆ Interval history of eye trauma, intraocular injection, or intraocular surgery 42, 62 The eye examination should emphasize the following elements: 31, 33 Even when a patient has had adequate treatment, additional examinations are important.
Between 5% and 14% of patients found to have an initial retinal break will develop additional breaks during long-term follow-up. These statistics appear to be similar regardless of how the initial breaks were treated. 33, 106 New breaks may be particularly likely in eyes that have had cataract surgery. 33 All patients at increased risk of retinal detachment should be instructed to notify their ophthalmologist as soon as possible if they have a substantial change in symptoms, such as an increase in floaters, loss of visual field, or decrease in visual acuity. 41, 42, 77, 109 If patients are familiar with the symptoms of retinal tears or detachment, they may be more likely to report promptly, thus improving the opportunity for successful treatment and subsequent visual results. 17 Patients who undergo refractive surgery to reduce myopia should be informed that they remain at risk of RRD despite reduction of their refractive error.
Limited data exist on the socioeconomic impacts of PVD, retinal breaks, or lattice degeneration.
However, research on the impact of the symptoms of these conditions (e.g., vitreous floaters) has suggested that vitreous symptoms may have an unfavorable effect on a patient's vision-related quality of life. 110, 111 The modeled cost of evaluating a patient with PVD and treating associated pathology in Providing quality care is the physician's foremost ethical obligation, and is the basis of public trust in physicians. AMA Board of Trustees, 1986 Quality ophthalmic care is provided in a manner and with the skill that is consistent with the best interests of the patient. The discussion that follows characterizes the core elements of such care.
The ophthalmologist is first and foremost a physician. As such, the ophthalmologist demonstrates compassion and concern for the individual, and utilizes the science and art of medicine to help alleviate patient fear and suffering. The ophthalmologist strives to develop and maintain clinical skills at the highest feasible level, consistent with the needs of patients, through training and continuing education. The ophthalmologist evaluates those skills and medical knowledge in relation to the needs of the patient and responds accordingly. The ophthalmologist also ensures that needy patients receive necessary care directly or through referral to appropriate persons and facilities that will provide such care, and he or she supports activities that promote health and prevent disease and disability.
The ophthalmologist recognizes that disease places patients in a disadvantaged, dependent state. The ophthalmologist respects the dignity and integrity of his or her patients and does not exploit their vulnerability.
Quality ophthalmic care has the following optimal attributes, among others.
◆ The essence of quality care is a meaningful partnership relationship between patient and physician. The ophthalmologist strives to communicate effectively with his or her patients, listening carefully to their needs and concerns. In turn, the ophthalmologist educates his or her patients about the nature and prognosis of their condition and about proper and appropriate therapeutic modalities. This is to ensure their meaningful participation (appropriate to their unique physical, intellectual, and emotional state) in decisions affecting their management and care, to improve their motivation and compliance with the agreed plan of treatment, and to help alleviate their fears and concerns. ◆ The ophthalmologist uses his or her best judgment in choosing and timing appropriate diagnostic and therapeutic modalities as well as the frequency of evaluation and follow-up, with due regard to the urgency and nature of the patient's condition and unique needs and desires.
◆ The ophthalmologist carries out only those procedures for which he or she is adequately trained, experienced, and competent, or, when necessary, is assisted by someone who is, depending on the urgency of the problem and availability and accessibility of alternative providers. ◆ Patients are assured access to, and continuity of, needed and appropriate ophthalmic care, which can be described as follows.  The ophthalmologist treats patients with due regard to timeliness, appropriateness, and his or her own ability to provide such care.  The operating ophthalmologist makes adequate provision for appropriate pre-and postoperative patient care.  When the ophthalmologist is unavailable for his or her patient, he or she provides appropriate alternate ophthalmic care, with adequate mechanisms for informing patients of the existence of such care and procedures for obtaining it.  The ophthalmologist refers patients to other ophthalmologists and eye care providers based on the timeliness and appropriateness of such referral, the patient's needs, the competence and qualifications of the person to whom the referral is made, and access and availability.
 The ophthalmologist seeks appropriate consultation with due regard to the nature of the ocular or other medical or surgical problem. Consultants are suggested for their skill, competence, and accessibility. They receive as complete and accurate an accounting of the problem as necessary to provide efficient and effective advice or intervention, and in turn they respond in an adequate and timely manner. The ophthalmologist maintains complete and accurate medical records.  On appropriate request, the ophthalmologist provides a full and accurate rendering of the patient's records in his or her possession.  The ophthalmologist reviews the results of consultations and laboratory tests in a timely and effective manner and takes appropriate actions.  The ophthalmologist and those who assist in providing care identify themselves and their profession.  For patients whose conditions fail to respond to treatment and for whom further treatment is unavailable, the ophthalmologist provides proper professional support, counseling, rehabilitative and social services, and referral as appropriate and accessible. ◆ Prior to therapeutic or invasive diagnostic procedures, the ophthalmologist becomes appropriately conversant with the patient's condition by collecting pertinent historical information and performing relevant preoperative examinations. Additionally, he or she enables the patient to reach a fully informed decision by providing an accurate and truthful explanation of the diagnosis; the nature, purpose, risks, benefits, and probability of success of the proposed treatment and of alternative treatment; and the risks and benefits of no treatment. ◆ The ophthalmologist adopts new technology (e.g., drugs, devices, surgical techniques) in judicious fashion, appropriate to the cost and potential benefit relative to existing alternatives and to its demonstrated safety and efficacy. ◆ The ophthalmologist enhances the quality of care he or she provides by periodically reviewing and assessing his or her personal performance in relation to established standards, and by revising or altering his or her practices and techniques appropriately. (2) retrolental, transvitreal, and epiretinal membranes and strands;
(3) chorioretinal pigment alterations; (4) lattice degeneration, often with a perivascular component that extends posteriorly; and (5) various other abnormalities including glaucoma and cataract. Systemic features include a generalized skeletal dysplasia, often with a marfanoid habitus, flattened facies, high arched or cleft palate, hearing loss, and other extracranial skeletal anomalies, many of which can be very subtle. The inheritance pattern is autosomal dominant, and a gene defect has been related to COL2A1.
Subclinical retinal detachment:
A retinal detachment that extends more than 1 disc diameter from the posterior edge of the retinal break, less than 2 disc diameters from the equator, and does not impair the field of vision.
Vitreoretinal adhesion (VMA):
A firm attachment between the cortical vitreous and the inner surface of the retina. Condensed vitreous strands adhering to the retina may sometimes be visualized using biomicroscopy or indirect ophthalmoscopy and scleral depression. Traction of the vitreous on the retina during PVD may cause retinal breaks to occur at these sites.
Vitreomacular traction (VMT):
Partial vitreous separation from the retina resulting in mechanical distortion of the macula.
VMA: See Vitreomacular adhesion

VMT: See Vitreomacular traction
Zonular traction retinal tufts: Small congenital lesions of the peripheral retina caused by thickened zonules that have been displaced posteriorly to the anterior retina.
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